secwatch.observer — SEC 8-K summary
======================================

Issuer:     SEELOS THERAPEUTICS, INC. (—)
CIK:        0001017491
Form:       8-K
Filed at:   2023-05-26T23:59:59+00:00
Accession:  0001104659-23-065442
Event type: regulatory
Sentiment:  negative
Materiality: 0.85
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Seelos receives Nasdaq delisting notice; plans to appeal and may pursue reverse stock split
--------------------------------------------------------------------------------

- Nasdaq notified Seelos on May 23, 2023 that it failed to regain compliance with $1.00 bid price rule.
- Company is ineligible for a second 180-day compliance period because stockholders' equity is below $5M.
- Seelos will request a hearing by May 30, 2023, staying suspension until the panel rules.
- Hearing plan may include a reverse stock split to regain compliance with Rule 5550(a)(2).
- If appeal is denied, common stock will be delisted from Nasdaq Capital Market.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1017491/000110465923065442/0001104659-23-065442-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1017491/000110465923065442/tm2317105d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-065442

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer